Previous 10 | Next 10 |
There is plenty of discussion about AbbVie's ( ABBV ) recent proposal to acquire Allergan ( AGN ). The deal appears to be highly polarizing: some love it, some hate it. Which camp you fall into seems to depend on how much of a cynic you are. Those who love the deal see two companies with enorm...
AbbVie ( ABBV ) has reached a deal to acquire Allergan ( AGN ) as mega deals appear to be back in today's pharmaceutical market. The deal is not welcomed at all by the market for the right reasons, as the strategic rationale can be questioned, a huge premium is paid, and the deal jacks up leve...
After a rocky May, it appears June will finish on strong footing. Of course, these days looking at any short-term trading range is meaningless as we have witnessed extreme volatility the last several months. Up a few hundred points one day, down a few hundred the next. Where can we find stabil...
AbbVie (NYSE: ABBV ) recently announced a plan to acquire Allergan (NYSE: AGN ) for more than $60 billion. That's a sharp drawdown from Pfizer's (NYSE: PFE ) offer to buy the company for $160 billion in 2015, a deal that ultimately didn't work out after tax law changes ended one of the ...
Today's top stories: G20 summit takes center stage; Ive leaving Apple; and stress tests. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking Alpha Podcasts here ) Stitcher SoundCloud ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). G20 optimism boosts stocks , G20 tensions weigh on equities... While that's most of the rhetoric inve...
By Jonathan Weber Pharmaceutical giant AbbVie Inc. ( ABBV ) has been one of our top-ranked dividend stocks for an extended period. We have written previously about our three pillars of expected returns , and AbbVie is attractive across the three pillars. The stock is undervalued, the co...
Somewhat unnoticed in the stock action following the AbbVie ( ABBV ) deal to purchase Allergan ( AGN ) was the surging yield of the acquiring stock. The size and scale of the debt load from the deal caused investors to panic, but AbbVie is a bargain now as the dividend yield surged 6.5%. ...
News broke Tuesday morning (first at the Wall Street Journal , I believe) that AbbVie (ABBV) has agreed to acquire Allergan (AGN). This is one of the larger pharma mergers of recent years, and regular readers of this site will have a pretty good idea of the sigh and roll of the eyes with wh...
Hey everyone. Hope life has continued to treat you great. Today I am writing you in regard to the newest purchase in our dividend portfolio . I made the purchase on Friday and was thrilled with the buy, and then Tuesday came around and now I'm happy but also kind of questioning it. Things h...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET About to begin a phase 2b/3 multinational study of Ifenprodil Algernon Pharmaceuticals is a drug repurposing company. They're a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential thera...
2024-03-27 17:08:02 ET A stroke can be a devastating and debilitating event for an individual and their family, and a major burden on the health care system. Over 15 million people suffer strokes every year, and 85% of those have some form of disability as a result. Stroke-related cos...
2024-03-27 17:08:02 ET Stocks to Invest in: Healthcare Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease Algernon is a drug re-purposing company that investigates safe, already approved drugs, inclu...